Scarica l'app Stockscreener
45.25
2.17%
0.96
Dopo l'orario di chiusura:
45.50
0.25
+0.55%
Precedente Chiudi:
$44.29
Aprire:
$44.2
Volume 24 ore:
1.33M
Relative Volume:
1.01
Capitalizzazione di mercato:
$3.64B
Reddito:
$541.74M
Utile/perdita netta:
$88.01M
Rapporto P/E:
41.66
EPS:
1.0862
Flusso di cassa netto:
$155.34M
1 W Prestazione:
+8.28%
1M Prestazione:
-18.63%
6M Prestazione:
+23.67%
1 anno Prestazione:
+58.16%
Intervallo 1D:
$44.19
$45.50
Intervallo di 1 settimana:
$41.02
$45.50
Portata 52W:
$28.55
$60.91
Veracyte Inc Stock (VCYT) Company Profile
Nome
Veracyte Inc
Settore
Industria
Telefono
(650) 243-6300
Indirizzo
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, NTRA, A, IQV
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
45.25 | 3.36B | 541.74M | 88.01M | 155.34M | 1.0862 |
TMO
Thermo Fisher Scientific Inc
|
630.70 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.68 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
338.70 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
157.69 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
262.38 | 42.15B | 16.63B | 1.39B | 2.12B | 8.0674 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-13 | Iniziato | Jefferies | Buy |
| 2025-12-02 | Ripresa | Morgan Stanley | Underweight |
| 2025-10-20 | Iniziato | Canaccord Genuity | Hold |
| 2025-03-20 | Iniziato | Craig Hallum | Buy |
| 2024-12-05 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-16 | Iniziato | UBS | Buy |
| 2024-10-10 | Iniziato | Guggenheim | Buy |
| 2024-02-23 | Reiterato | Needham | Buy |
| 2023-01-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2021-11-18 | Ripresa | Goldman | Buy |
| 2021-06-15 | Iniziato | Raymond James | Outperform |
| 2021-02-18 | Ripresa | Needham | Buy |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | Iniziato | Morgan Stanley | Underweight |
| 2019-07-31 | Iniziato | Lake Street | Buy |
| 2019-07-02 | Iniziato | Needham | Buy |
| 2018-11-29 | Downgrade | Janney | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Janney | Neutral → Buy |
| 2017-11-07 | Downgrade | Janney | Buy → Neutral |
| 2017-11-07 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | Ripresa | BTIG Research | Buy |
| 2016-11-14 | Ripresa | Leerink Partners | Outperform |
| 2015-12-18 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-06-11 | Reiterato | Leerink Partners | Outperform |
| 2013-11-26 | Iniziato | William Blair | Outperform |
Mostra tutto
Veracyte Inc Borsa (VCYT) Ultime notizie
Virtus Advisers LLC Purchases New Shares in Veracyte, Inc. $VCYT - MarketBeat
Great Lakes Advisors LLC Invests $3.85 Million in Veracyte, Inc. $VCYT - MarketBeat
Veracyte (VCYT): Moves 0.50% Down to $41.98 on the Day; Trading Range: the Price Remains Bounded by the Supplied Support and ResistanceDividend Arbitrage - vinanet.vn
Lisanti Capital Growth LLC Purchases Shares of 63,400 Veracyte, Inc. $VCYT - MarketBeat
Top 3 Health Care Stocks That Could Blast Off This Month - Benzinga
Summit Creek Advisors LLC Takes Position in Veracyte, Inc. $VCYT - MarketBeat
Veracyte (VCYT) Results at a Glance: EPS Clears the Reported Estimate in Latest Trading; Stock Move: Shares Move Lower 2.50%Investor Earnings Call - vinanet.vn
Rice Hall James & Associates LLC Invests $5.61 Million in Veracyte, Inc. $VCYT - MarketBeat
Veracyte Inc (VCYT) News, Articles, Events & Latest Updates - Stocktwits
Down 30.2% in 4 Weeks, Here's Why Veracyte (VCYT) Looks Ripe for a Turnaround - Yahoo Finance
Is Veracyte (VCYT) Undervalued As Raised 2026 Outlook And Q2 Earnings Lift Interest? - Sahm
Veracyte Inc (VCYT) Shares Fall 3.2% -- GF Value Says Still Over - GuruFocus
Veracyte Debuts Prosigna Breast Test in the U.S. - Medical Product Outsourcing
Zacks Research Upgrades Veracyte (NASDAQ:VCYT) to Strong-Buy - MarketBeat
Bank of America Corp DE Grows Stock Position in Veracyte, Inc. $VCYT - MarketBeat
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo Finance
A Look at Veracyte Inc (VCYT) After 3.7% Decline -- GF Value $38 - GuruFocus
Amundi Sells 116,588 Shares of Veracyte, Inc. $VCYT - MarketBeat
How Investors May Respond To Veracyte (VCYT) Raising 2026 Revenue Guidance After Returning To Profit - Sahm
Veracyte at canaccord growth conference: growth balanced with margins By Investing.com - Investing.com Canada
Veracyte at canaccord growth conference: growth balanced with margins - Investing.com
Veracyte (VCYT) Dropped, So What Is Behind The Latest Attention? - Sahm
Veracyte: Diagnostics With Favorable Economics (NASDAQ:VCYT) - Seeking Alpha
Veracyte: Core Growth Funds Prosigna And TrueMRD (NASDAQ:VCYT) - Seeking Alpha
Royal Bank of Canada Grows Stock Holdings in Veracyte, Inc. $VCYT - MarketBeat
Veracyte, Inc. $VCYT Shares Sold by Janus Henderson Group PLC - MarketBeat
CCORF Maintains Veracyte(VCYT.US) With Hold Rating, Cuts Target Price to $50 - Moomoo
Empowered Funds LLC Buys 68,171 Shares of Veracyte, Inc. $VCYT - MarketBeat
Results: Veracyte, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Veracyte (NASDAQ:VCYT) Shows Affordable Growth Potential - ChartMill
Renaissance Technologies LLC Takes Position in Veracyte, Inc. $VCYT - MarketBeat
VERACYTE INC : PIPER SANDLER CUTS TARGET PRICE TO $54.00 FROM $66.00 - Bitget
Medicare Coverage Granted for Veracyte’s Test for Muscle-Invasive Bladder Cancer - Medical Product Outsourcing
Guggenheim Reaffirms Their Buy Rating on Veracyte (VCYT) - The Globe and Mail
Stephens Issues Pessimistic Forecast for Veracyte (NASDAQ:VCYT) Stock Price - MarketBeat
Veracyte (NASDAQ:VCYT) Price Target Cut to $44.00 by Analysts at Morgan Stanley - MarketBeat
Veracyte, Inc. (VCYT): Investor Outlook Reveals a 31.35% Potential Upside Amid Strong Analyst Ratings - DirectorsTalk Interviews
Arrowstreet Capital Limited Partnership Takes Position in Veracyte, Inc. $VCYT - marketbeat.com
Veracyte (VCYT) Is Down 18.2% After Raising 2026 Revenue Guidance on New Cancer Tests - webull.com
Canaccord cuts Veracyte stock price target to $50 on revenue outlook - Investing.com Nigeria
VERACYTE INC : CANACCORD GENUITY CUTS TARGET PRICE TO $50 FROM $60 - Bitget
Veracyte (VCYT) Plunges 22.5%: Critical Support Level in Focus After Steep SelloffDouble Top - Vinanet
VERACYTE, INC. 2026: Revenue $150.32M, EPS $0.31— 10-Q Summary - TradingView
Veracyte | 10-Q: Q2 2026 Earnings Report - Moomoo
Piper Sandler Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $66 - moomoo.com
Needham raises Veracyte stock price target to $69 on strong Q2 beat - Investing.com Nigeria
Veracyte (NASDAQ:VCYT) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
Transcript : Veracyte, Inc., Q2 2026 Earnings Call, Jul 30, 2026 - marketscreener.com
Is Veracyte Inc (VCYT) Still a Strong Investment After Q2 Earnin - GuruFocus
Earnings call transcript: Veracyte beats Q2 2026 estimates but shares fall after hours - Investing.com
Veracyte Q2 Non-GAAP Earnings, Revenue Rise; 2026 Revenue Guidance Raised - Moomoo
Veracyte Inc Azioni (VCYT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):